Navigation Links
CSIRO deal to commercialize 'artificial gut'
Date:6/9/2009

CSIRO Food Futures National Research Flagship and Australian company Stadvis Pty Ltd have signed a worldwide license agreement to commercialise an automated instrument that accurately predicts glycemic index (GI) and resistant starch (RS) in food products.

The machine will provide the food industry with an accurate means of testing the functional properties and potential human health benefits of new foods that is much quicker and more cost-effective than the current in vivo (human) method.

The GI and RS Analyser is the first of its kind in the world. The prototype works by mimicking the human digestion process and was originally developed to test the properties of new grains being developed by the Flagship.

Dr Bruce Lee, Director of the Food Futures Flagship, said this commercialisation agreement will help address the growing global demand for foods with defined health benefits through low GI and higher fibre content particularly resistant starch.

"Its principal purpose is to help food manufacturers develop a wider range of healthy food products far more cheaply and quickly than possible previously. It can also be used to screen germplasm for functional grain attributes," Dr Lee said.

"With the growing problem of obesity, diabetes and cardiovascular disease in Australia and around the world, there is increasing demand for low GI and foods high in resistant starch. Consumers need greater access to products with appropriate health benefits, and we believe this new GI and RS predictor will help achieve that goal," he said.

CSIRO awarded the license to commercialise the machine following an open Expression of Interest announcement by the CSIRO. Stadvis Managing Director, Mr Phillip Clancy, said the new instrument will be a valuable addition to his company's portfolio.

"Stadvis is pleased to have won the opportunity to partner with CSIRO to bring this technology to market. The new device will be marketed to food manufacturing companies and laboratories around the world," he said.

Until now predicting GI involved feeding the test food to a number of human volunteers and taking regular blood samples over the following hours to monitor changing blood sugar levels. This new machine can replace this expensive and time consuming process in the development phase of products, leaving the standard in vivo (human) test to the final stage of food development and labelling procedures.

CSIRO initiated the National Research Flagships to provide science-based solutions in response to Australia's major research challenges and opportunities. The nine Flagships form multidisciplinary teams with industry and the research community to deliver impact and benefits for Australia.


'/>"/>

Contact: Owen Craig
Owen.Craig@csiro.au
61-294-908-201
CSIRO Australia
Source:Eurekalert  

Related biology news :

1. CSIRO enlisted to avert global wheat supply crisis
2. MSU technology that converts plant fibers to biofuel commercialized
3. Progress toward artificial tissue?
4. Non-wovens as scaffolds for artificial tissue
5. Development of an artificial simulator of the nervous system to do research into diseases
6. Red pandas reveal an unexpected (artificial) sweet tooth
7. Artificial cells, simple model for complex structure
8. TECNALIA uses artificial vision to improve recycling of electronic scrap metal
9. Biomedical researchers create artificial human bone marrow in a test tube
10. Scientists identify cell changes leading to impaired artificial kidney function
11. Evolved Machines Selected as a Prime Contractor for DARPA Program to Engineer an Artificial Olfaction System
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CSIRO deal to commercialize 'artificial gut'
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... -- According to the new market ... Instruments, Automated Cell Expansion System), Cells Types (Human, ... Cancer, and Cell-Based Research), End-users (Biopharmaceutical and Biotechnology ... Trends, Growth, Share, Size and Forecast to 2022", ... expansion market is expected to reach USD 18.74 ...
(Date:12/5/2016)... Mich. , Dec. 5, 2016 NxGen MDx announced today ... bringing the test in house, we,ve been able to improve customer service ... for patients," says Alan Mack , CEO of NxGen MDx. ... , , ... test volume has led to more job opportunities at the Grand Rapid ...
(Date:12/5/2016)... -- The U.S. Biotechnology industry is the ... revenue and some $890 billion of total market value. In ... and this figure is expected to exceed $220 billion ... four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ACOR ...
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
Breaking Biology Technology: